These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 35202156

  • 1. Crystal Structures of Botulinum Neurotoxin Subtypes A4 and A5 Cell Binding Domains in Complex with Receptor Ganglioside.
    Gregory KS, Mojanaga OO, Liu SM, Acharya KR.
    Toxins (Basel); 2022 Feb 08; 14(2):. PubMed ID: 35202156
    [Abstract] [Full Text] [Related]

  • 2. Crystal structure of botulinum neurotoxin subtype A3 cell binding domain in complex with GD1a co-receptor ganglioside.
    Gregory KS, Liu SM, Acharya KR.
    FEBS Open Bio; 2020 Mar 08; 10(3):298-305. PubMed ID: 31945264
    [Abstract] [Full Text] [Related]

  • 3. Structural Features of Clostridium botulinum Neurotoxin Subtype A2 Cell Binding Domain.
    Gregory KS, Mahadeva TB, Liu SM, Acharya KR.
    Toxins (Basel); 2022 May 19; 14(5):. PubMed ID: 35622602
    [Abstract] [Full Text] [Related]

  • 4. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR, Rees J, Liu SM, Acharya KR.
    J Struct Biol; 2018 May 19; 202(2):113-117. PubMed ID: 29288126
    [Abstract] [Full Text] [Related]

  • 5. Crystal Structures of the Clostridium botulinum Neurotoxin A6 Cell Binding Domain Alone and in Complex with GD1a Reveal Significant Conformational Flexibility.
    Gregory KS, Newell AR, Mojanaga OO, Liu SM, Acharya KR.
    Int J Mol Sci; 2022 Aug 25; 23(17):. PubMed ID: 36077016
    [Abstract] [Full Text] [Related]

  • 6. High-resolution crystal structures of the botulinum neurotoxin binding domains from subtypes A5 and A6.
    Davies JR, Britton A, Liu SM, Acharya KR.
    FEBS Open Bio; 2020 Aug 25; 10(8):1474-1481. PubMed ID: 32654405
    [Abstract] [Full Text] [Related]

  • 7. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F.
    Fu Z, Chen C, Barbieri JT, Kim JJ, Baldwin MR.
    Biochemistry; 2009 Jun 23; 48(24):5631-41. PubMed ID: 19476346
    [Abstract] [Full Text] [Related]

  • 8. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
    Kroken AR, Blum FC, Zuverink M, Barbieri JT.
    Infect Immun; 2017 Jan 23; 85(1):. PubMed ID: 27795365
    [Abstract] [Full Text] [Related]

  • 9. Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors.
    Davies JR, Masuyer G, Stenmark P.
    Toxins (Basel); 2020 Sep 17; 12(9):. PubMed ID: 32957706
    [Abstract] [Full Text] [Related]

  • 10. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
    Kull S, Schulz KM, Weisemann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dorner MB, Barr JR, Rummel A, Dorner BG.
    PLoS One; 2015 Sep 17; 10(2):e0116381. PubMed ID: 25658638
    [Abstract] [Full Text] [Related]

  • 11. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M, Schulze S, Strotmeier J, Mahrhold S, Richter K, Binz T, Bigalke H, Ahnert-Hilger G, Rummel A.
    Toxicon; 2013 Dec 01; 75():108-21. PubMed ID: 23817019
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the functional activity of botulinum neurotoxin subtype B6.
    Kohda T, Nakamura K, Hosomi K, Torii Y, Kozaki S, Mukamoto M.
    Microbiol Immunol; 2017 Nov 01; 61(11):482-489. PubMed ID: 28898517
    [Abstract] [Full Text] [Related]

  • 13. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.
    mBio; 2018 Mar 27; 9(2):. PubMed ID: 29588398
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of Ganglioside Receptor Recognition by Botulinum Neurotoxin Serotype E.
    Masuyer G, Davies JR, Stenmark P.
    Int J Mol Sci; 2021 Aug 02; 22(15):. PubMed ID: 34361086
    [Abstract] [Full Text] [Related]

  • 15. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.
    Rummel A, Mahrhold S, Bigalke H, Binz T.
    Mol Microbiol; 2004 Feb 02; 51(3):631-43. PubMed ID: 14731268
    [Abstract] [Full Text] [Related]

  • 16. Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.
    James NG, Malik S, Sanstrum BJ, Rhéaume C, Broide RS, Jameson DM, Brideau-Andersen A, Jacky BS.
    Sci Rep; 2021 Apr 09; 11(1):7832. PubMed ID: 33837264
    [Abstract] [Full Text] [Related]

  • 17. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
    Ayyar BV, Aoki KR, Atassi MZ.
    Infect Immun; 2015 Apr 09; 83(4):1465-76. PubMed ID: 25624352
    [Abstract] [Full Text] [Related]

  • 18. Unique ganglioside recognition strategies for clostridial neurotoxins.
    Benson MA, Fu Z, Kim JJ, Baldwin MR.
    J Biol Chem; 2011 Sep 30; 286(39):34015-22. PubMed ID: 21849494
    [Abstract] [Full Text] [Related]

  • 19. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.
    Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.
    J Biol Chem; 2012 Nov 23; 287(48):40806-16. PubMed ID: 23027864
    [Abstract] [Full Text] [Related]

  • 20. Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics.
    Davies JR, Liu SM, Acharya KR.
    Toxins (Basel); 2018 Oct 20; 10(10):. PubMed ID: 30347838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.